Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on 4D Molecular Therapeutics (FDMT – Research Report). The associated price target remains the same with $36.00.
Matthew Caufield has given his Buy rating due to a combination of factors related to the promising developments in 4D Molecular Therapeutics’ gene therapy program. The company is advancing its intravitreal 4D-150 therapy into near-term Phase 3 trials following positive interim data from a Phase 2b trial in wet AMD patients, which showed promising results in terms of efficacy and safety.
The anticipated initiation of pivotal trials, 4FRONT-1 and 4FRONT-2, in 2025, along with a strong cash runway projected into 2028, supports the company’s ability to sustain its development efforts. The trials aim to demonstrate the benefits of 4D-150, including reduced treatment burden compared to standard anti-VEGF injections, which could lead to significant clinical benefits for patients. The diversity of the patient population and the specific trial design further enhance the potential for successful outcomes, reinforcing the Buy rating and a price target of $36.
According to TipRanks, Caufield is an analyst with an average return of -13.3% and a 28.78% success rate. Caufield covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Opus Genetics, and Opthea Limited Sponsored ADR.